Shalby Limited has confirmed that none of its promoters or promoter group entities have encumbered their equity shares in the company during the financial year 2025-26. The disclosure was submitted to the National Stock Exchange of India Ltd and BSE Limited on April 07, 2026, in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The filing explicitly states that no encumbrance was created directly or indirectly on the shares held by the promoters during the period ended March 31, 2026. This confirmation is part of the company's mandatory annual disclosure requirements regarding the shareholding status of its promoters.

The communication was addressed to the Listing Departments of both exchanges and was digitally signed by Tushar Shah, AVP & Company Secretary of Shalby Limited. The company requested the exchanges to place the disclosure on record.

Shalby Limited returned to profitability in the fourth quarter of FY26, reporting a consolidated net profit of ₹18.5 crores against a loss of ₹12.2 crores in the corresponding period of the previous year. The company's revenue from operations rose to ₹295.5 crores year-on-year, registering a growth of 9.4%, driven by growth across its hospital and MedTech verticals. Operational efficiency improved notably, with EBITDA growing to ₹37.4 crores from ₹26.2 crores in Q4 FY25, and the EBITDA margin expanding to 12.7% from 9.7%. For the full year FY26, consolidated revenue grew to ₹1,168.2 crores, while net profit stood at ₹34.7 crores.

Consolidated Performance Highlights

The financial turnaround was supported by robust performance in the standalone business and the implant manufacturing segment. The adoption of the new tax regime during the period influenced the profitability metrics, reducing the tax rate to 25% from 35%. The table below summarises the key consolidated financial metrics for the quarter:

Segment and Operational Performance

Shalby Hospitals, Pharma & Franchise contributed 79.16% to the consolidated revenue at ₹2,339.5 million, while Shalby MedTech recorded a 45% year-on-year jump in revenue to ₹40 crores. The standalone entity reported a 7.6% increase in quarterly revenue to ₹230.4 crores, with a net profit of ₹53.7 crores. On the operational front, the hospital business saw a rise in surgery counts, with Arthroplasty procedures growing by 15.4% year-on-year to over 2,650 surgeries in Q4 FY26.

MedTech and International Business

Shalby MedTech delivered a significant turnaround in profitability, reporting a positive EBITDA of ₹3.7 crores compared to a loss of ₹9.3 crores in Q4 FY25. For the full year FY26, the segment achieved a positive EBITDA of ₹6.7 crores against a loss of ₹19.2 crores in FY25. The international business faced headwinds due to geopolitical situations impacting patient inflows to the Gurugram unit, though growth in African and CIS countries provided some offset. The group completed 70 transplants during FY26, including 51 kidney and 19 liver transplants.

Statutory Auditor's Report

M/s. T R Chadha & Co LLP, Chartered Accountants, issued an unmodified opinion on the standalone and consolidated financial results. The report confirmed that the statements give a true and fair view of the financial position and performance of the company in conformity with applicable accounting standards.

Regulatory Disclosure

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted the copies of the advertisement published on May 29, 2026, in the Financial Express for the audited financial results. The results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 27, 2026. A transcript of the earnings conference call held on May 29, 2026, was also submitted to the exchanges.